BT-062 is a chimerized, toxin-coupled therapeutic monoclonal antibody, which, based on the current state of knowledge, binds to a target molecule on the cell surface of the multiple myeloma cells and thus destroys them.

• Target indication (multiple myeloma)
• Upside indications: other solid tumors